Primary extranodal Non-Hodgkin`s lymphoma presenting as painful gingval swelling

Primary extra-nodal non-Hodgkin’s lymphomas (NHL) constitute 25–40% of NHL but less than 1% arises in oral cavity. Here in 53-year-old man with stage IE gingival diffuse large B cell lymphoma who was treated successfully with chemotherapy and radiotherapy was presented

Kikuchi — Fujimoto disease: cervical lymphadenopathy suggestive of relapsing lymphoma in patient with lymphoblastic lymphoma

Aim: Kikuchi — Fujimoto disease (KFD) or histiocytic necrotizing lymphadenitis is a rare disorder and often confused with lymphoma. Patient: There is presented a case of 28-year-old patient with cervical lymphadenopathy, who had history of lymphoma. Results: On immunohistopathologic examination diagnosis of KFD was made and patient followed without any treatment. Conclusion: Patient’s lymphadenopathy had almost resolved and he was completely asymptomatic after three months. In patient with cervical lymphadenopathy KFD should be considered in the differential diagnosis

TIMP-2 gene transfer by positively charged PEG-lated monosized polycationic carrier to smooth muscle cells

Remodeling of the extracellular matrix resulting from increased secretion of metalloproteinase enzymes is implicated in restenosis following balloon angioplasty. Matrix metalloproteinases (MMPs) and the tissue inhibitors of metalloproteinases play an essential role in both normal and pathological extracellular matrix degradation. Tissue inhibitor of matrix metalloproteinase- 2 is the most extensively studied tissue inhibitor of metalloproteinases inmyocardial tissue in animalmodels and clinical examples of cardiac disease; therefore it is selected for this study. Gene transfer of tissue inhibitor of matrix metalloproteinase-2 may have a therapeutic potential by inhibition of matrix metalloproteinase activity. We have used PEG-lated nanoparticles poly(St/PEG-EEM/DMAPM) which were synthesized previously in our laboratory. The nanoparticles, with an average size of 77.6 ± 2.05 nm with a zeta potential of +64. 4 ± 1.14 mVand 201.9 ± 1.83 nmwith +54.2 ± 0.77 mV were used in the transfection studies. Zeta Potential values and size of polyplex were appropriate for an effective transfection. TIMP-2 expression was detected by western blotting. Increased protein level in smoothmuscle cells according to non-transfected smooth muscle cells confirms the successful delivery and expression of the tissue inhibitor of matrix metalloproteinase- 2 gene with the non-viral vector transfection approach. © Springer Science+Business Media B.V. 2012

Simple Precision Creation of Digitally Specified, Spatially Heterogeneous, Engineered Tissue Architectures

Complex architectures of integrated circuits are achieved through multiple layer photolithography, which has empowered the semiconductor industry. We adapt this philosophy for tissue engineering with a versatile, scalable, and generalizable microfabrication approach to create engineered tissue architectures composed of digitally specifiable building blocks, each with tuned structural, cellular, and compositional features.Paul G. Allen Family FoundationNew York Stem Cell FoundationNational Institutes of Health (U.S.)National Science Foundation (U.S.)Lincoln LaboratoryInstitution of Engineering and Technology (AF Harvey Prize

Two cases with atypical metastasis in colorectal cancer: splenic and renal metastasis

Atypical metastasis, such as splenic and renal metastasis is rare in colorectal cancer. There have been case reports of colorectal cancer patients with isolated splenic metastasis, even after years of surgery in the literature. Aim: To report two colorectal cancer cases with atypical metastasis

Blood viscosity in patients with diffuse large B cell non-Hodgkin’s lymphoma

The aim of the study was to evaluate blood viscosity as possible marker of disease progression in patients with newly diagnosed non-Hodgkin’s lymphoma (NHL). Methods: The viscosity of blood samples from 20 patients with newly diagnosed aggressive NHL (stage I, n = 7; stage II, n = 4; stage III, n = 7; stage IV, n = 2) was analyzed using Brookfield DV-II + (USA) machine. Results: Blood viscosity in NHL patients (median: 5.5 ± 1.46 miliPascal) inversely correlated with lactatdehydrogenase (LDH) level, international prognostic index (IPI) score, and stage (p = 0.02, r= –0.51; p = 0.03, r= –0.63; and p = 0.04, r= –0.45, respectively) and positively correlated with hemoglobin level (p = 0.02, r = 0.65)). Conclusion: According to our data, blood viscosity may be considered as a follow up marker in NHL patients along with LDH level or sedimentation rate.Цель: анализ вязкости крови в качестве маркера возможного маркера прогрессии заболевания у больных неходжкинской лимфомой (НХЛ). Методы: вязкость крови 20 пациентов НХЛ (стадия I, = 7; стадия II, = 4; стадия III, = 7; стадия  IV, n = 4) измеряли на приборе Brookfield DV-II + (США). Результаты: вязкость крови больных НХЛ (средняя величина: 5.5 ± 1.46 миллиПаскаль) находилась в обратной корреляции с уровнем лактатдегидрогеназы (ЛДГ), величиной международного прогностического индекса (IPI) и стадией заболевания (p = 0,02, r = –0,51; p = 0,03, r = –0,63; p = 0,04, r = –0,45 соответственно) и в прямой зависимости от уровня гемоглобина (p = 0,02, = 0,65)). Выводы: согласно полученным данным, вязкость крови можно рассматривать в качестве маркера течения заболевания у больных НХЛ наряду с уровнем ЛДГ и показателем скорости оседания эритроцитов

Assessing population diversity in phase III trials of cancer drugs supporting Food and Drug Administration approval in solid tumors

Our study aimed to assess inequities in the clinical trial participation for the selected patient groups. We searched the Food and Drug Administration (FDA) database and extracted phase-III clinical trial data from MEDLINE for each approved drug by the FDA between January 1, 2006, and June 30, 2020. We analyzed the inclusion/exclusion criteria, participation according to gender, ethnic group, performance score, the positivity of HBV and HCV, and HIV, having comorbidities and brain metastasis. We compared the findings with that of the general population by retrieving data from the Surveillance, Epidemiology and End Results (SEER) database. We identified 142 phase III pivotal oncology trials that enrolled 105 397 patients. The proportion of female patients in trials was lower than their relative prevalence in the general population from SEER region (36% vs 49.6%, P < .001). The rates of black patients included were lower than their relative prevalence from SEER region (2.1% vs 9.8%, P < .001). 1.3% and 0.8% of patients had HBV and HCV infections, respectively. The patients' numbers with organ dysfunction were not established due to insufficient data from clinical trials. 1.6% of all patients had controlled brain metastasis. Black patients, women and patients with brain metastasis or with HBV and HCV were underrepresented. Our study underscores the importance of expanding the inclusion/exclusion criteria of pivotal oncology trials to be more representative of patients seen in clinical practice

The role of cardiac biomarkers as predictors of trastuzumab cardiotoxicity in patients with breast cancer

Aim: Identification of patient with increased risk of cardiotoxicity would allow not only prevention and early diagnosis of chemotherapy related cardiotoxicity but also administration of optimal dose and duration of chemotherapy. Materials and methods: Fifty-two women with HER2+ breast cancer treated with trastuzumab were included in this study. Patients were prospectively followed with routine cardiac evaluation. Before and after administration of trastuzumab blood samples for NT-proBNP were also taken. Results: The median age was 48.5 year (range: 26–74). Hypertension and obesity were two most common co-morbidities. The median duration application of trastuzumab was 52 weeks. During median 14.5 (3–33) months follow-up cardiac adverse events occurred in 5 (9.6%) patients and 2 out of 5 was grade III–IV heart failure. Both patients had preserved left ventricular ejection fraction and no symptom of heart failure before trastuzumab but older than 65 years old and had diabetes mellitus and obesity. High level of NT-proBNP (> 300 ng/ml) was observed in both patients and heart failure recovery was not observed. There was statistically significant difference regarding body mass index (p = 0.004) and diabetes mellitus (p = 0.002) between patients with and without cardiotoxicity. Conclusion: Although, cardiac biomarkers still cannot replace routine cardiac monitoring, natriuretic peptides may provide additional tool for detection of patients with high risk of cardiotoxicity and early detection of cardiotoxicity. Key Words: breast cancer, trastuzumab, heart failure, left ventricular dysfunction, natriuretic peptides

Modified capitonage in partial cystectomy performed for liver hydatid disease: Report of 2 cases

BACKGROUND: Several techniques have been described in liver hydatid disease surgery, with most well known partial cystectomy, capitonage and introflexion. METHODS: We present a technical modification on open partial cystectomy for liver hydatid disease. We performed this operation in 2 patients with liver echinococcosis. The cyst is being unroofed and evacuated from the daughter cysts. The identified bile vessels ligated. The remnants of the anterior wall (capsule of the cyst) are anchored with sutures in the posterior wall in a manner that the cavity of the cyst disappears. RESULTS: In both patients the disease eradicated. No postoperative complications were observed including bile leaking and/or abscess formation. CONCLUSIONS: Our technique helps in the fast, and effective mobilization of the patient, as well as in the minimization of postoperative bile leaking

Engineered 3D tissue models for cell-laden microfluidic channels

Abstract Delivery of nutrients and oxygen within threedimensional (3D) tissue constructs is important to maintain cell viability. We built 3D cell-laden hydrogels to validate a new tissue perfusion model that takes into account nutrition consumption. The model system was analyzed by simulating theoretical nutrient diffusion into cell-laden hydrogels. We carried out a parametric study considering different microchannel sizes and inter-channel separation in the hydrogel. We hypothesized that nutrient consumption needs to be taken into account when optimizing the perfusion channel size and separation. We validated the hypothesis by experiments. We fabricated circular microchannels (r= 400 μm) in 3D cell-laden hydrogel constructs (R = 7.5 mm, volume=5 ml). These channels were positioned either individually or in parallel within hydrogels to increase nutrient and oxygen transport as a way to improve cell viability. We quantified the spatial distribution of viable cells within 3D hydrogel scaffolds without channels and with single-and dual-perfusion microfluidic channels. We investigated quantitatively the cell viability as a function of radial distance from the channels using experimental data and mathematical modeling of diffusion profiles. Our simulations show that a large-channel radius as well as a large channel to channel distance diffuse nutrients farther through a 3D hydrogel. This is important since our results reveal that there is a close correlation between nutrient profiles and cell viability across the hydrogel